WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising an effective amount of an antigen-binding protein construct (ABPC) comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell,

wherein:

(a) the dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or

(b) the dissociation constant (K_D) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the K_D at a pH of about 7.0 to about 8.0.

2. The pharmaceutical composition of claim 1, wherein the ABPC is degraded in the target mammalian cell following internalization of the ABPC by the target mammalian cell.

3. The pharmaceutical composition of claim 1 or 2, wherein the ABPC further comprises a conjugated toxin, radioisotope, drug, or small molecule.

4. A pharmaceutical composition comprising an effective amount of an antigen-binding protein construct (ABPC) comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell; and

a conjugated toxin, radioisotope, drug, or small molecule,

wherein:

(a) the dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or

the dissociation constant (K_D) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the K_D at a pH of about 7.0 to about 8.0; and

(b) the composition provides for one or more of:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC;

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control ABPC; and

an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC.

5. The pharmaceutical composition of claim 1 or 4, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a heavy chain variable domain of Telisotuzumab with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of Telisotuzumab comprises SEQ ID NO: 1; and/or

a light chain variable domain of Telisotuzumab with one or more amino acids substituted with a histidine, wherein the light chain variable domain of Telisotuzumab comprises SEQ ID NO: 2;

(b) a heavy chain variable domain of Emibetuzumab with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of Emibetuzumab comprises SEQ ID NO: 146; and/or

a light chain variable domain of Emibetuzumab with one or more amino acids substituted with a histidine, wherein the light chain variable domain of Emibetuzumab comprises SEQ ID NO: 147;

(c) a heavy chain variable domain of hucMET27Gvl.3 with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of hucMET27Gvl.3 comprises SEQ ID NO: 304; and/or

a light chain variable domain of hucMET27Gvl.3 with one or more amino acids substituted with a histidine, wherein the light chain variable domain of hucMET27Gvl.3 comprises SEQ ID NO: 305; and

(d) a heavy chain variable domain of P3D12 with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of P3D12 comprises SEQ ID NO: 502; and/or

a light chain variable domain of P3D12 with one or more amino acids substituted with a histidine, wherein the light chain variable domain of P3D12 comprises SEQ ID NO: 503.

6. The pharmaceutical composition of claim 1 or 4, wherein the first MET-binding domain comprises one of (a) through (d):

(a) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 3-5, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 3-5 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 6-8, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 6-8 substituted with a histidine;

(b) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 148-150, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 148-150 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 151-153, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 151-153 substituted with a histidine;

(c) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 306-308, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 306-308 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 309-311, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 309-311 substituted with a histidine; and

(d) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 504-506, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 504-506 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 507-509, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 507-509 substituted with a histidine.

7. The pharmaceutical composition of any one of claims 1 and 4-6, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

(b) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

(c) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101; and

(d) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96. 97, and 98.

8. The pharmaceutical composition of claim 1 or 4, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a light chain variable domain of SEQ ID NO: 2, SEQ ID NO: 52, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO:

71, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140, and/or

a heavy chain variable domain of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 94, or SEQ ID NO: 111,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain of SEQ ID NO: 1; (ii) a light chain variable domain of SEQ ID NO: 2 and heavy chain variable domain that is not one of SEQ ID NOs: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94, and 111; or (iii) a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain that is not one of SEQ ID NOs: 52, 55-59, 61-67, 71, 72, 75, 79, 81, and 131-140;

(b) a light chain variable domain of SEQ ID NO: 147, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300, or SEQ ID NO: 301, and/or

a heavy chain variable domain of SEQ ID NO: 146, SEQ ID NO: 159, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 187, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, or SEQ ID NO: 236,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain of SEQ ID NO: 146; (ii) a light chain variable domain of SEQ ID NO: 147 and heavy chain variable domain that is not one of SEQ ID NOs: 159, 164-168, 170, 171, 173, 182-184, 187, 217-228, and 230-236; or (iii) a heavy chain variable domain of SEQ ID NO: 146 and a light chain variable domain that is not one of SEQ ID NOs: 190, 191, 194, 197, 198, 200, 201, 209, 210, 213-215, 284-298, 300 and 301;

(c) a light chain variable domain of SEQ ID NO: 305, SEQ ID NO: 352, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 360, SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 457, SEQ ID NO: 462, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID NO: 479, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID NO: 496, or SEQ ID NO: 499, and/or

a heavy chain variable domain of SEQ ID NO: 304, SEQ ID NO: 313, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, or SEQ ID NO: 400,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain of SEQ ID NO: 304; (ii) a light chain variable domain of SEQ ID NO: 305 and heavy chain variable domain that is not one of SEQ ID NOs: 313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393, and 395-400; or (iii) a heavy chain variable domain of SEQ ID NO: 304 and a light chain variable domain that is not one of SEQ ID NOs: 352, 356, 357, 360, 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428-446, 450, 451, 453, 457, 462, 463, 465, 470, 472-474, 476, 479, 482, 483, 485, 490, 492, 494, 496, and 499; and

(d) a light chain variable domain of SEQ ID NO: 503, SEQ ID NO: 550, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 562, SEQ ID NO: 565, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572, SEQ ID NO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO: 699, SEQ ID NO: 700, SEQ ID NO: 701, SEQ ID NO: 702, SEQ ID NO: 703, SEQ ID NO: 704, SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707, SEQ ID NO: 708, SEQ ID NO: 709, SEQ ID NO: 710, SEQ ID NO: 711, SEQ ID NO: 712, SEQ ID NO: 713, or SEQ ID NO: 732, and/or

a heavy chain variable domain of SEQ ID NO: 502, SEQ ID NO: 511, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, SEQ ID NO: 519, SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 527, SEQ ID NO: 529, SEQ ID NO: 538, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO: 581, SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 587, SEQ ID NO: 588, SEQ ID NO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO: 597, SEQ ID NO: 606, SEQ ID NO: 621, SEQ ID NO: 659, or SEQ ID NO: 676,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain of SEQ ID NO: 502; or (ii) a light chain variable domain of SEQ ID NO: 503 and heavy chain variable domain that is not one of SEQ ID NOs: 511, 513, 514, 516-523, 527, 529, 538, 540-543, 546, 547, 578-597, 606, 621, 659, and 676; or (iii) a heavy chain variable domain of SEQ ID NO: 502 and light chain variable domain that is not one of SEQ ID NOs: 550, 554, 556-560, 562, 565, 569, 570-576, 697-713, and 732.

9. The pharmaceutical composition of any one of claims 1-8, wherein the composition provides for:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC; and/or

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control ABPC.

10. The pharmaceutical composition of any one of claims 1-9, wherein the composition provides for an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC.

11. The pharmaceutical composition of any one of claims 1-10, wherein the composition:

results in a less of a reduction in the level of MET presented on the surface of the target mammalian cell as compared to a composition comprising the same amount of a control ABPC; or

does not result in a detectable reduction in the level of MET presented on the surface of the target mammalian cell.

12. The pharmaceutical composition of any one of claims 1-11, wherein the target mammalian cell is a cancer cell.

13. The pharmaceutical composition of any one of claims 1-12, wherein the ABPC is cytotoxic or cytostatic to the target mammalian cell.

14. The pharmaceutical composition of any one of claims 1-13, wherein the ABPC is: cross-reactive with a non-human primate MET and human MET; or

cross-reactive with a non-human primate MET, a human MET, and one or both of rat MET and a mouse MET.

15. The pharmaceutical composition of any one of claims 1-14, wherein the ABPC comprises a single polypeptide.

16. The pharmaceutical composition of claim 15, wherein the antigen-binding domain is selected from the group consisting of: a VH domain, a VHH domain, a VNAR domain, and a scFv.

17. The pharmaceutical composition of any one of claims 1-14, wherein the ABPC comprises two or more polypeptides.

18. The pharmaceutical composition of claim 17, wherein the ABPC is an antibody.

19. The pharmaceutical composition of any of claims 1-18, wherein the half-life of the ABPC in vivo is decreased as compared to the half-life of a control ABPC in vivo.

20. The pharmaceutical composition of any one of claims 1-19, wherein the ABPC further comprises a second antigen-binding domain.

21. An antigen-binding protein construct (ABPC) comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell,

wherein:

(a) the dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or

(b) the dissociation constant (KD) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the KD at a pH of about 7.0 to about 8.0.

22. The ABPC of claim 21, wherein the ABPC is degraded in the target mammalian cell following internalization of the ABPC by the target mammalian cell.

23. The ABPC of claim 21 or 22, wherein the ABPC further comprises a conjugated toxin, radioisotope, drug, or small molecule.

24. An antigen-binding protein construct (ABPC) comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell; and

a conjugated toxin, radioisotope, drug, or small molecule,

wherein:

(a) the dissociation rate of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is faster than the dissociation rate at a pH of about 7.0 to about 8.0; or

the dissociation constant (K_D) of the first antigen-binding domain at a pH of about 4.0 to about 6.5 is greater than the K_D at a pH of about 7.0 to about 8.0; and

(b) the composition provides for one or more of:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC;

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control ABPC; and

an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC.

25. The ABPC of claim 21 or 24, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a heavy chain variable domain of Telisotuzumab with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of Telisotuzumab comprises SEQ ID NO: 1; and/or

a light chain variable domain of Telisotuzumab with one or more amino acids substituted with a histidine, wherein the light chain variable domain of Telisotuzumab comprises SEQ ID NO: 2;

(b) a heavy chain variable domain of Emibetuzumab with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of Emibetuzumab comprises SEQ ID NO: 146; and/or

a light chain variable domain of Emibetuzumab with one or more amino acids substituted with a histidine, wherein the light chain variable domain of Emibetuzumab comprises SEQ ID NO: 147;

(c) a heavy chain variable domain of hucMET27Gvl.3 with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of hucMET27Gvl.3 comprises SEQ ID NO: 304; and/or

a light chain variable domain of hucMET27Gvl.3 with one or more amino acids substituted with a histidine, wherein the light chain variable domain of hucMET27Gvl.3 comprises SEQ ID NO: 305; and

(d) a heavy chain variable domain of P3D12 with one or more amino acids substituted with a histidine, wherein the heavy chain variable domain of P3D12 comprises SEQ ID NO: 502; and/or

a light chain variable domain of P3D12 with one or more amino acids substituted with a histidine, wherein the light chain variable domain of P3D12 comprises SEQ ID NO: 503.

26. The ABPC of claim 21 or 24, wherein the first MET-binding domain comprises one of (a) through (d):

(a) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 3-5, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 3-5 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 6-8, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 6-8 substituted with a histidine;

(b) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 148-150, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 148-150 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 151-153, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 151-153 substituted with a histidine;

(c) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 306-308, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 306-308 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 309-311, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 309-311 substituted with a histidine; and

(d) a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 504-506, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 504-506 substituted with a histidine; and/or

a light chain variable domain comprising a CDR1, a CDR2, and a CDR3 of SEQ ID NOs: 507-509, respectively, with collectively a total of one or more amino acid positions in SEQ ID NOs: 507-509 substituted with a histidine.

27. The ABPC of any one of claims 21 and 24-26, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

(b) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

(c) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101; and

(d) a heavy chain variable domain that is at least 90% identical to SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107; and/or

a light chain variable domain that is at least 90% identical to SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96. 97, and 98.

28. The ABPC of claim 21 or 24, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a light chain variable domain of SEQ ID NO: 2, SEQ ID NO: 52, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140, and/or

a heavy chain variable domain of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 94, or SEQ ID NO: 111,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain of SEQ ID NO: 1; (ii) a light chain variable domain of SEQ ID NO: 2 and heavy chain variable domain that is not one of SEQ ID NOs: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94, and 111; or (iii) a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain that is not one of SEQ ID NOs: 52, 55-59, 61-67, 71, 72, 75, 79, 81, and 131-140;

(b) a light chain variable domain of SEQ ID NO: 147, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300, or SEQ ID NO: 301, and/or

a heavy chain variable domain of SEQ ID NO: 146, SEQ ID NO: 159, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 187, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, or SEQ ID NO: 236,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain of SEQ ID NO: 146; (ii) a

light chain variable domain of SEQ ID NO: 147 and heavy chain variable domain that is not one of SEQ ID NOs: 159, 164-168, 170, 171, 173, 182-184, 187, 217-228, and 230-236; or (iii) a heavy chain variable domain of SEQ ID NO: 146 and a light chain variable domain that is not one of SEQ ID NOs: 190, 191, 194, 197, 198, 200, 201, 209, 210, 213-215, 284-298, 300 and 301;

(c) a light chain variable domain of SEQ ID NO: 305, SEQ ID NO: 352, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 360, SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 457, SEQ ID NO: 462, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID NO: 479, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID NO: 496, or SEQ ID NO: 499, and/or

a heavy chain variable domain of SEQ ID NO: 304, SEQ ID NO: 313, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, or SEQ ID NO: 400,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain of SEQ ID NO: 304; (ii) a light chain variable domain of SEQ ID NO: 305 and heavy chain variable domain that is not one of SEQ ID NOs: 313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393, and 395-400; or (iii) a heavy chain variable domain of SEQ ID NO: 304 and a light chain variable domain that is not one of SEQ ID NOs: 352, 356, 357, 360, 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428-446, 450, 451, 453, 457, 462, 463, 465, 470, 472-474, 476, 479, 482, 483, 485, 490, 492, 494, 496, and 499; and

(d) a light chain variable domain of SEQ ID NO: 503, SEQ ID NO: 550, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 562, SEQ ID NO: 565, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572, SEQ ID NO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO: 699, SEQ ID NO: 700, SEQ ID NO: 701, SEQ ID NO: 702, SEQ ID NO: 703, SEQ ID NO: 704, SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707, SEQ ID NO: 708, SEQ ID NO: 709, SEQ ID NO: 710, SEQ ID NO: 711, SEQ ID NO: 712, SEQ ID NO: 713, or SEQ ID NO: 732, and/or

a heavy chain variable domain of SEQ ID NO: 502, SEQ ID NO: 511, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, SEQ ID NO: 519, SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 527, SEQ ID NO: 529, SEQ ID NO: 538, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO: 581, SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 587, SEQ ID NO: 588, SEQ ID NO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO: 597, SEQ ID NO: 606, SEQ ID NO: 621, SEQ ID NO: 659, or SEQ ID NO: 676,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain of SEQ ID NO: 502; or (ii) a light chain variable domain of SEQ ID NO: 503 and heavy chain variable domain that is not one of SEQ ID NOs: 511, 513, 514, 516-523, 527, 529, 538, 540-543, 546, 547, 578-597, 606, 621, 659, and 676; or (iii) a heavy chain variable domain of SEQ ID NO: 502 and light chain variable domain that is not one of SEQ ID NOs: 550, 554, 556-560, 562, 565, 569, 570-576, 697-713, and 732.

29. The ABPC of any one of claims 21-28, wherein a composition comprising the ABPC provides for:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC; and/or

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control ABPC.

30. The ABPC of any one of claims 21-29, wherein a composition comprising the ABPC provides for an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control ABPC.

31. The ABPC of any one of claims 21-30, wherein a composition comprising the ABPC:

results in a less of a reduction in the level of MET presented on the surface of the target mammalian cell as compared to a composition comprising the same amount of a control ABPC; or

does not result in a detectable reduction in the level of MET presented on the surface of the target mammalian cell.

32. The ABPC of any one of claims 21-31, wherein the target mammalian cell is a cancer cell.

33. The ABPC of any one of claims 21-32, wherein the ABPC is cytotoxic or cytostatic to the target mammalian cell.

34. The ABPC of any one of claims 21-33, wherein the ABPC is:

cross-reactive with a non-human primate MET and human MET; or

cross-reactive with a non-human primate MET, a human MET, and one or both of rat

MET and a mouse MET.

35. The ABPC of any one of claims 21-34, wherein the ABPC comprises a single polypeptide.

36. The ABPC of claim 35, wherein the antigen-binding domain is selected from the group consisting of: a VH domain, a VHH domain, a VNAR domain, and a scFv.

37. The ABPC of any one of claims 21-34, wherein the ABPC comprises two or more polypeptides.

38. The ABPC of claim 37, wherein the ABPC is an antibody.

39. The ABPC of any of claims 21-38, wherein the half-life of the ABPC *in vivo* is decreased as compared to the half-life of a control ABPC *in vivo*.

40. The ABPC of any one of claims 21-39, wherein the ABPC further comprises a second antigen-binding domain.

41. A kit comprising at least one dose of the pharmaceutical composition of any one of claims 1-20 or the ABPC of any one of claims 21-40.

42. A pharmaceutical composition of any one of claims 1 to 20 or an ABPC of any one of claims 21 to 40 for use in the treatment of a cancer in a subject characterized by having a population of cancer cells that have MET or an epitope of MET presented on their surface.

43. A pharmaceutical composition of any one of claims 1 to 20 or an ABPC of any one of claims 21 to 40 for use in reducing the volume of a tumor in a subject, wherein the tumor is characterized by having a population of cancer cells that have MET or an epitope of MET presented on their surface.

44. A pharmaceutical composition of any one of claims 1 to 20 or an ABPC of any one of claims 21 to 40 for use in inducing cell death in a cancer cell in a subject, wherein the cancer cell has MET or an epitope of MET presented on its surface.

45. A pharmaceutical composition of any one of claims 1 to 20 or an ABPC of any one of claims 21 to 40 for use in decreasing the risk of developing a metastasis or decreasing the risk of developing an additional metastasis in a subject having a cancer, wherein the cancer is characterized by having a population of cancer cells that have MET or an epitope of MET presented on their surface.